Mental Health Blogs

Yesterday and today have got to be red-letter days in stupidity at the FDA. Yesterday, the agency approved the antipsychotic Seroquel as an add-on treatment for depression. Today, the agency approved Zyprexa, the controversial diabetes-inducing antipsychotic, for use in adolescents aged 13 to 17 who are diagnosed with schizophrenia or who have manic or mixed episodes of bipolar disorder. Zyprexa has been widely used off-label for these two indications in people younger than 18 for years and with the drug going off-patent in less than 18 months, it’s not clear to me what these new indications do for Lilly.

I have little else to say. I am so thoroughly disgusted by two days of dubious approvals by the FDA that I want to go sit in a corner and vomit.

Go to Source

Related posts:

1. What Happened To Seroquel’s Approval For Depression?
2. Here Comes Another New Antipsychotic
3. Lilly May Settle Zyprexa Claims With More States
4. New Zyprexa Documents Show Lilly Ghostwrote Zyprexa Studies
5. Utah Settles Zyprexa Claims For $24 Million